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Key points
† Patients undergoing
cardiopulmonary bypass
(CPB) may develop
dilutional coagulopathy.
† The value of prothrombin
complex concentrate in
reducing suture hole
bleeding from the carotid
artery was assessed in
pigs after CPB.
† The prothrombin complex
concentrate reduced
bleeding.
† This agent may be useful
in the clinical setting.
Background. Extracorporeal circuit priming and intravascular volume expansion during
cardiopulmonary bypass (CPB) may lead to dilutional coagulopathy and excessive diffuse
postoperative bleeding. Prothrombin complex concentrate (PCC) containing clotting
factors II (FII), VII (FVII), IX (FIX), and X (FX) could be of potential value in correcting
dilutional coagulopathy and reducing blood loss.
Methods. Anaesthetized pigs underwent CPB with hypothermia for 2 h at 258C followed by
1 h of normothermia. Approximately 1 h after CPB, animals randomly received either
isotonic saline 1 ml kg
21 or PCC 30 IU kg
21 in a volume of 1 ml kg
21. Diffuse
coagulopathic bleeding was assessed as suture hole blood loss from a Gore-Tex patch
placed over a full-thickness incision in the left carotid artery.
Results. After CPB, levels of FII, FVII, FIX, and FX declined from baseline by 32% to 48%, and
PCC fully or partially reversed those deﬁcits. Median suture hole blood loss after
administration of saline placebo was 74 ml. PCC reduced suture hole bleeding by a
median of 54 ml with a 95% conﬁdence interval of 6–112 ml (P¼0.026) compared with
saline. PCC, but not saline, normalized skin bleeding time. Peak thrombin generation
markedly decreased after CPB, but then returned in PCC-treated animals to a level higher
than baseline by 28.7 nM (14.5–41.1 nM; P¼0.031).
Conclusions. PCC was effective in correcting dilutional coagulopathy and reducing diffuse
bleeding in an in vivo large-animal CPB model. Further research is warranted on PCC as a
haemostatic agent in CPB.
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Excessive postoperative bleeding remains a frequent, serious,
and unpredictable complication of cardiac surgery with car-
diopulmonary bypass (CPB).
1–4 Such bleeding is often
non-surgical. For instance, diffuse oozing with no identiﬁable
surgical site of bleeding was present in 42 of 191 consecutive
CPB patients (22%) undergoing re-exploration for excessive
blood loss.
2
Dilution of coagulation factors may contribute to exces-
sive haemorrhage post-CPB.
5 Commencement of CPB precipi-
tates an abrupt major haemodilution due to extracorporeal
circuit priming with ﬂuid volumes typically of  2000 ml or
more. More than 2000 ml of additional ﬂuids may be admi-
nistered during surgery, further exacerbating haemodilution.
As a consequence, the estimated dilution of plasma clotting
factors resulting from CPB surgery is  50%.
5
Prothrombin complex concentrate (PCC) could be of
potential utility in correcting dilutional coagulopathy
arising during CPB. The ability of PCC to ameliorate
diffuse coagulopathic bleeding has already been demon-
strated in a study of general surgery patients.
6 In that
study, 27 patients with life-threatening diffuse bleeding
and an international normalized ratio (INR) above 1.1
received Beriplex P/N, a biochemically well-characterized
balanced PCC containing coagulation factors II (FII), VII
(FVII), IX (FIX), and X (FX), and the anticoagulant proteins
Ca n dS .
7 Cessation of bleeding was attained in 26 patients
(96%) within 3 h of PCC administration. Clinical evidence on
the use of Beriplex P/N in cardiac surgery has also been
provided by case reports, a retrospective study, and a
randomized trial.
8–10
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Advance Access publication 17 August 2010 . doi:10.1093/bja/aeq216A conventional option for correcting haemodilution-
induced coagulation factor deﬁciencies after CPB is transfu-
sion of fresh-frozen plasma (FFP), which contains all the
coagulation factors. However, since FII, FVII, FIX, and FX
are present in Beriplex P/N at  25 times the corresponding
plasma concentrations, smaller volumes and less time are
needed to correct dilutional coagulopathy compared with
FFP. Also, FFP requires thawing, and blood type matching
may also be needed. Furthermore, most FFP preparations
have not been virally inactivated. In the puriﬁcation of Beri-
plex P/N, such inactivation is accomplished by pasteurization
and nanoﬁltration of plasma screened by polymerase chain
reaction.
71 1There has been no evidence in clinical trials of
viral transmission related to Beriplex P/N infusion.
12 13 The
present study evaluated the ability of Beriplex P/N to attenu-
ate diffuse post-CPB bleeding in a porcine model.
Methods
Animals
Seventeen castrated male pigs (large white×German noble)
weighing 24–40 kg were procured from a local breeding farm
(Willi Schlosser, Schwalmtal, Germany) at age 3–4 months.
The animals were housed at 18–218C in stables with straw
bedding under ambient day–night cycles and fed ad
libitum with Deuka V pig chow (Deutsche Tiernahrung
Cremer GmbH & Co., KG, Du ¨sseldorf, Germany). Tap water
was supplied ad libitum. Animal husbandry and study pro-
cedures complied with the German Animal Welfare law and
European Union regulations. The study was approved by
the regional government authorities.
Anaesthesia
Anaesthetic procedures have been previously described.
14
Brieﬂy, after an overnight fast with unrestricted access to
water and i.m. premedication using a mixture of azaperone
2m gk g
21 (Stresnil
w, Janssen-Cilag GmbH, Neuss, Germany),
ketamine 15 mg kg
21 (Ketavet, Pharmacia & Upjohn, Erlan-
gen, Germany), and atropine sulphate 0.02 mg kg
21 (Atropin-
sulfate, B. Braun Melsungen AG, Melsungen, Germany), the
pigs were anaesthetized with thiopental sodium 10 mg kg
21
via an ear vein. After tracheal intubation, respiration was sup-
ported via a Heyer Access ventilator. Inhaled anaesthesia was
maintained with isoﬂurane 1–2% (Isoﬂuran CP
w, CP Pharma
GmbH, Burgdorf, Germany). Attainment and maintenance of
deepanaesthesiawereconﬁrmedbyanabsentpedalwithdra-
wal reﬂex and lack of any response to surgery. A 1.4×2.1 mm
catheter was advanced into a carotid artery for collection of
blood samples and a 0.5×0.9 mm catheter into a femoral
artery for continuous arterial pressure measurements.
Ringer’ssolutionat4mlkg
21h
21tosatisfybasalﬂuidrequire-
ments and test ﬂuids were infused via an indwelling 1.4×2.1
mm catheter in an external jugular vein. Body temperature
was monitored by rectal thermometry.
Cardiopulmonary bypass
The experimental design is outlined in Figure 1. Sternotomy
was performed with an oscillating saw, and the heart was
exposed. The pericardium was opened longitudinally and
secured to the chest wall with four sutures. Two purse-string
sutures each were placed in the ascending aorta and right
atrium. An i.v. bolus of heparin 300 U kg
21 was administered.
After 10 min, a 5.2 mm diameter arterial catheter and a 32 Fr
venous catheter were placed and secured with tourniquets.
Both catheters were connected to a small adult hollow ﬁbre
oxygenator with a hard shell venous reservoir (D905 EOS,
Sorin SpA, Milan, Italy). The extracorporeal circuit was
primed with a solution consisting of isotonic saline 500 ml,
6% hydroxyethyl starch 200/0.5 1000 ml (Infukoll, Schwarz
Pharma AG, Mannheim, Germany), 15% mannitol 2 ml kg
21
(Osmofundin
w,B.Braun)andheparin1000units.Hydroxyethyl
starchhasbeenextensivelyinvestigatedforprimingincardiac
surgery randomized trials
15 andis acommonchoice inclinical
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Fig 1 Study design. CPB, cardiopulmonary bypass; PCC, prothrombin complex concentrate; SBT, skin bleeding time.
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16 17Thevenousandarteriallineswereopenedinsuc-
cession and the venous blood allowed to ﬂow into the venous
reservoir by gravity. An arterial pump conveyed the blood into
the oxygenator. The oxygenated blood was equilibrated to
target temperature and returned via the arterial line to the
aorta. Hypothermia was maintained at 258C for 2 h followed
by 1 h of normothermia (378C).
Patch placement
Polytetraﬂuorethylene (PTFE) is a commonly used graft
material in vascular surgery. Gore-Tex is a PTFE-based
material. Oozing from the multiple suture holes created
when securing PTFE grafts can often lead to substantial
cumulative blood loss.
18 Suture hole bleeding is thus similar
in nature to the diffuse oozing typical of non-surgical post-
operative haemorrhage in cardiac surgery patients.
Methods of patch placement have been detailed else-
where.
19 During the period of normothermia, the left carotid
artery was occluded with two clamps 5 cm apart. After a full-
thicknessincisionintothearterialwall,aGore-Texpatch4mm
wide and  30 mm long (W.L. Gore & Associates GmbH, Putz-
brunn, Germany) was sutured to the incision site with 5/0
monoﬁlament (Ethicon GmbH, Norderstedt, Germany).
Treatment
Upon termination of CPB, the blood remaining in the oxyge-
nator was returned to the animal. Anticoagulation was
reversed with protamine sulphate 1 mg per 100 units of admi-
nistered heparin. Study treatment ﬂuids were infused 55 min
thereafter. Six animals each were randomly assigned to
receive isotonic saline 1 ml kg
21 or PCC 30 IU kg
21 (Beriplex
w
P/N, CSL Behring GmbH, Marburg, Germany) in a volume of
1m lk g
21. As an additional control group, ﬁve animals were
subjected to carotid patch placement but not CPB.
Measurements
Immediately after test ﬂuid infusion, the carotid clamps were
released. The volume of blood shed from the suture holes
was measured. Additionally, the time elapsed from clamp
release until cessation of observable suture hole bleeding
was recorded as the time to haemostasis.
Blood samples for laboratory assays were collected at (i)
baseline before the commencement of CPB, (ii) 5 min after
reversal of anticoagulation with protamine, and (iii) 5 min
after test ﬂuid infusion. At those time points, determinations
were also made of skin bleeding time (SBT), deﬁned as the
time until cessation of blood loss from a standardized 5 mm
longby1mmdeepinnerearincisioncreatedusingaSurgicutt
w
cuttingdevice(InternationalTechnidyneCorp.,Edison,NJ,USA).
Concentrations of coagulation factors were measured in
coagulation factor-deﬁcient plasma (Dade Behring,
Marburg, Germany) with a Schnitger and Gross coagulometer
(Heinrich Amelung GmbH, Lemgo, Germany). Measurement
of FII, FVII, FIX, and FX in porcine plasma using assays
designed for human samples has been previously
described.
14 20–22 Prothrombin time (PT) was determined
using a Schnitger & Gross coagulometer and the Thromborel
reagent (Dade Behring).
Peak thrombin generation was measured by calibrated
automated thrombinography (Thrombinoscope B.V., Maas-
tricht, The Netherlands) in diluted plasma.
23 The respective
concentrations of recombinant relipidated tissue factor and
phospholipids were 5 pM and 4 mM. The peak molar quantity
of thrombin present in clotting plasma was computed using
the Thrombinoscope software version 3.0.0.29.
Statistical analysis
On the basis of previously reported suture hole blood loss
measurements in the pig with or without ﬁbrin sealant,
19 it
was assumed that an effective treatment would reduce blood
loss on average by 50 ml with a standard deviation of 25 ml.
On the basis of that assumption, a sample size of six animals
per group was calculated to furnish .80% statistical power
for detecting a between-group difference at the 0.05 a-level.
Median differences and their 95% conﬁdence intervals (CI)
were calculated by exact Hodges–Lehmann estimation. The
statistical signiﬁcance of differences was evaluated by the
exact Wilcoxon test. Computer programs used for statistical
analysis were R version 2.7.2 (The R Foundation for Statistical
Computing, Vienna, Austria) and StatXact 7.0 (Cytel Software
Corp., Cambridge, MA, USA).
Results
Median PT was prolonged after CPB compared with baseline
(Table 1). After saline infusion, PT returned to approximately
the baseline level. PTafter PCC administration was shorter by
a median 2.6 s (CI, 2.1–4.2 s) than at baseline and by a
median 2.6 s (CI, 1.5–4.7 s) than after saline infusion. CPB
Table 1 PT, platelets, and SBT. CPB, cardiopulmonary bypass; IQR, inter-quartile range; PCC, prothrombin complex concentrate; PT, prothrombin
time; SBT, skin bleeding time
Category n Median (IQR)
PT (s) Platelets (310
9 litre
21) SBT (s)
Baseline 12 13.6 (13.0–14.4) 393 (347–482) 122 (110–130)
Post-CPB 12 15.4 (14.5–16.4) 254 (210–270) 172 (159–206)
Saline 6 13.8 (13.4–14.4) 284 (252–301) 166 (157–169)
PCC 6 11.3 (10.7–11.7) 239 (216–272) 138 (130–143)
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578decreased median platelet concentration to 254×10
9 from
393×10
9 litre
21 at baseline, and platelets remained low
both after saline and PCC infusion (Table 1).
Coagulation factors
After CPB, circulating levels of FII, FVII, FIX, and FX declined
from baseline by median values of 31.7% (CI, 18.4–44.4%),
35.5% (CI, 16.6–60.6%), 46.2% (CI, 28.2–59.4%), and
48.2% (CI, 24.5–55.1%), respectively (Fig. 2). In response to
PCC administration, FII, FVII, and FX rebounded to levels,
respectively, 82.5% (CI, 64.1–109.4%), 20.4% (CI, 3.8–
42.7%), and 51.7% (CI, 29.6–80.5%) above baseline. Com-
pared with the post-CPB levels, FIX increased 13.0% (CI,
5.7–18.0%) after PCC administration, but nevertheless
remained 33.8% (CI, 10.6–44.1%) below baseline.
As expected, the median decreases in the concentrations
of the four coagulation factors due to CPB-related haemodi-
lution were similar, all falling within the comparatively
narrow range of 31.7–48.2%. However, the concentration
changes in response to PCC infusion differed widely. Those
differences reﬂect both the relative proportions of the four
factors in the PCC and disparities in endogenous coagulation
factor concentrations between humans and pigs. The
respective mean (standard deviation) concentrations of FII,
FVII, FIX, and FX in Beriplex P/N are 31.0 (3.4), 16.2 (1.9),
28.9 (2.2), and 40.5 (3.3) IU ml
21.
12 The reported mean con-
centrations of those four coagulation factors in pigs, as per-
centages of normal human pooled plasma, are 45 (3), 83 (8),
330 (15), and 72 (4), respectively.
20 Consequently, when a
ﬁxed PCC dose was infused, its FIX component was added
to a high endogenous FIX concentration in the pig equalling
3.4-fold the human level, and the resulting per cent increase
in total measured FIX concentration was relatively small.
Similarly, the smaller median increase from baseline in FVII
(20.4%) than FII (82.5%) reﬂects both the two-fold higher
content of FII than FVII in the administered PCC and the
two-fold higher endogenous concentration of FVII than FII
in the pig.
Haemostasis
Figure 3 displays suture hole blood loss in animals treated
post-CPB either with saline placebo or PCC, and also in a
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Fig 2 Individual animal levels of (A) FII, (B) FVII, (C) FIX, and (D)F X
at baseline and after CPB and subsequent administration of PCC.
Concentration values expressed as percentages of the baseline
means, shown as dashed lines. CPB, cardiopulmonary bypass;
FII, factor II; FVII, factor VII; FIX, factor IX; FX, factor X; PCC, pro-
thrombin complex concentrate.
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Comparison Median difference (CI) (ml) P-value
No CPB vs saline 29 (–13 to 82) 0.23
No CPB vs PCC –23 (–57 to 18) 0.074
Saline vs PCC –54 (–112 to –6) 0.026
Fig 3 Individual animal suture hole blood losses after CPB and
administration of saline or PCC in comparison with those of a
control group which did not undergo CPB. Horizontal lines indi-
cate median values. CI, 95% conﬁdence interval; CPB, cardiopul-
monary bypass; PCC, prothrombin complex concentrate.
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loss after administration of saline placebo was 74 ml. Com-
pared with saline, PCC reduced blood loss by a median of
54 ml. The median time to suture hole haemostasis was
143 min (inter-quartile range, IQR, 142–172 min) in the
control group not subjected to CPB compared, respectively,
with 292 min (IQR, 247–328 min) and 217 min (IQR, 142–
288 min) after CPB and infusion of saline placebo or PCC.
Although time to haemostasis was shorter by a median of
69 min (CI, 2110 to 212 min) in the PCC than the saline
placebo group, the difference was not statistically signiﬁcant.
Median SBT was prolonged after CPB (172 s) vs baseline
(122 s), as summarized in Table 1. PCC normalized SBT
(P¼0.25 for paired comparison with baseline), whereas
after saline placebo administration, SBT remained signiﬁ-
cantly prolonged vs baseline by a median of 50 s (CI, 33–
68 s; P¼0.031).
Thrombin generation
CPB resulted in a marked attenuation of peak thrombin gen-
eration (Fig. 4). Infusion of saline exacerbated this effect,
whereas PCC increased peak thrombin generation to a level
higher than baseline by a median of 28.7 nM.
Discussion
In this randomized placebo-controlled animal model study,
PCC signiﬁcantly alleviated suture hole bleeding after CPB.
Such bleeding may simulate the diffuse oozing occurring in
many CPB patients who experience excessive postoperative
blood loss. The PCC-mediated reduction in suture hole bleed-
ing was accompanied by normalization of SBT and a pro-
nounced increase in peak thrombin generation.
This pilot study is limited by its relatively small size. The
results need to be conﬁrmed in further investigations, and
the optimal PCC regimen for use in CPB remains to be deli-
neated. The thrombogenic potential of PCC in CPB must
also be characterized.
PCC displayed haemostatic efﬁcacy in this study notwith-
standing a reduction in median platelet concentration to
254×10
9 litre
21. In a recent study of haemodilutional coagu-
lopathy and trauma in pigs,
22 PCC displayed haemostatic efﬁ-
cacy, despite an even more pronounced platelet reduction to
a mean of 133×10
9 litre
21. Additionally, in a clinical study of
16 consecutive intensive care unit patients, cessation of
bleeding was achieved after PCC administration in all cases,
despite a mean nadir platelet level of 149×10
9 litre
21.
24
Since decreases in platelet function and number are a hall-
mark of CPB, one potential attraction of PCC might be that
its effectiveness does not appear to be limited by compara-
tively low platelet counts.
A report of two cardiac surgery patients with liver dysfunc-
tion documented successful normalization of INR and cessa-
tion of excessive bleeding after infusion of Beriplex P/N.
8 In a
retrospective study, Beriplex P/N was administered to seven
cardiac surgery patients, ﬁve undergoing coronary artery
bypass graft and two valve procedures, who were experien-
cing bleeding refractory to FFP, platelets, and cryoprecipi-
tate.
9 Beriplex P/N shortened PT by 25% and activated
partial thromboplastin time by 38%, and partial or complete
haemostasis was achieved in all six patients with recorded
results for bleeding. In a newly reported randomized trial of
40 patients undergoing semi-urgent cardiac surgery with
CPB, Beriplex P/N was more effective than FFP for reversal
of oral anticoagulant therapy.
10
In previous clinical trials, Beriplex P/N has also proven
effective for emergency reversal of oral anticoagulant
therapy outside the setting of CPB.
13 25 Additionally, Beriplex
P/N showed haemostatic efﬁcacy among patients with clot-
ting factor deﬁcits due to severe liver disease who required
rapid haemostasis because of bleeding or the need for
urgent surgical or invasive diagnostic procedures.
26
In trauma, as in CPB, administered ﬂuids can produce dilu-
tional coagulopathy. In a porcine trauma model, PCC reduced
blood loss from traumatic bone and spleen injuries compared
with FFP
14 and accelerated haemostasis after spleen trauma
compared with recombinant activated FVII (rFVIIa).
22 In
those studies, PCC also increased peak thrombin generation
vs FFP and rFVIIa. Reduction in blood loss also resulted
from combination treatment with PCC and ﬁbrinogen in a
porcine model of haemodilutional coagulopathy and
Peak thrombin generat
ion (nM)
Baseline
Treatment
Saline PCC Post-CPB
0
20
40
60
80
100
120
Comparison Median difference (CI) (nM) P-value
Baseline vs post-CPB –21.6 (–26.8 to –18.1) <0.001
Baseline vs saline –24.0 (–44.0 to –17.4) 0.031
Baseline vs PCC 28.7 (14.5 to 41.1) 0.031
Post-CPB vs saline –3.6 (–5.3 to –1.9) 0.031
Post-CPB vs PCC 50.8 (43.3 to 56.0) 0.031
Saline vs PCC 53.9 (48.5 to 62.8) 0.002
Fig 4 Peak thrombin generation in individual animals at baseline
and after CPB and subsequent administration of saline or PCC.
Medians depicted as horizontal lines. In the table inset,
grouped comparison indicated between saline and PCC; all
other comparisons paired. CI, 95% conﬁdence interval; CPB, car-
diopulmonary bypass; PCC, prothrombin complex concentrate.
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580uncontrolled liver bleeding.
27 Similarly, in a rabbit model of
dilutional coagulopathy, PCC reduced blood loss and aug-
mented peak thrombin generation after kidney trauma com-
pared either with saline placebo or rFVIIa.
28 Importantly, at
effective dosages, PCC, unlike rFVIIa, showed no evidence
of thrombogenicity in that study, as evaluated using the
Wessler stasis model. Available clinical evidence also
suggests that the thrombogenic potential of PCC is low. In
a pharmacovigilance study, the estimated incidence of
thrombotic events among patients receiving PCC was 1.0
per 10
5 infusions (CI, 0.1–3.6 per 10
5 infusions).
29
rFVIIa has been evaluated in a recent randomized clinical
trial of 179 cardiac surgery patients with postoperative
bleeding.
30 The primary study endpoint was the incidence
of critical serious adverse events, deﬁned as either death or
thromboembolic complications. Owing to a trend towards
increasing critical serious adverse events after rFVIIa treat-
ment (odds ratio, 1.67; CI, 0.50–5.47), the investigators cau-
tioned that further clinical trials are required.
The pig has been extensively utilized as a model for eval-
uating haemostasis after administration of human PCC
14 21
22 and human rFVIIa.
22 31–38 Certain uncertainties are
inherent in such studies. The activity, bioavailability, or both
of the human protein might be attenuated in the porcine
host.
34 Assays of PT or thrombin generation optimized for
measurements of human samples may yield disparate
results in the pig. For instance, PT measured with a porcine-
speciﬁc assay is greater by over three-fold than with the
standard assay designed for human specimens.
37 39 The
porcine-speciﬁc assay revealed a nearly 50% prolongation
of PT during hypothermia, while no effect was detectable
by the standard assay method.
39 It is possible that the use
of the standard assay may account for the relatively small
impact of CPB on PT in the present study, despite the sub-
stantial increase in blood loss observed after CPB and
saline infusion. In any case, large absolute differences in PT
assay values may not translate into major differences in
the observed relative effects of human haemostatic proteins
in the pig model. Thus, despite an over three-fold absolute PT
difference at baseline, the average relative shortening of PT
by 90 mgk g
21 human rFVIIa was comparable when
measured by standard assay (64%) vs the porcine-speciﬁc
method (51%).
37
The thrombin generation assay used in the present study
was optimized for human samples, and the possibility cannot
be excluded of differences in results compared with those
that might have been generated by a porcine-speciﬁc
method. Nonetheless, assay differences could not have
affected bleeding, and the observed increase in thrombin
generation by PCC relative to saline was accompanied by a
corresponding decrease in blood loss. Furthermore, in two
pig studies of dilutional coagulopathy and trauma, human
PCC augmented thrombin generation compared with
human rFVIIa and with both standard- and high-dose
porcine PCC.
14 22 In both studies, corresponding acceleration
of haemostasis by PCC vs those control agents was
demonstrated.
In light of the data reviewed above, PCC appears to be a
versatile haemostatic agent suitable for use in indications
involving multiple clotting factor deﬁciencies. Further clinical
studies are needed to deﬁne the appropriate role for PCC in
CPB. The present results provide encouragement to embark
upon such studies.
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